Sunday, May 28, 2023
SCIENMAG: Latest Science and Health News
No Result
View All Result
  • Login
  • HOME PAGE
  • BIOLOGY
  • CHEMISTRY AND PHYSICS
  • MEDICINE
    • Cancer
    • Infectious Emerging Diseases
  • SPACE
  • TECHNOLOGY
  • CONTACT US
  • HOME PAGE
  • BIOLOGY
  • CHEMISTRY AND PHYSICS
  • MEDICINE
    • Cancer
    • Infectious Emerging Diseases
  • SPACE
  • TECHNOLOGY
  • CONTACT US
No Result
View All Result
Scienmag - Latest science news from science magazine
No Result
View All Result
Home SCIENCE NEWS Chemistry AND Physics

Treating a rare genetic disorder that causes colon cancer in children

November 20, 2018
in Chemistry AND Physics
0
Share on FacebookShare on Twitter

IMAGE

Credit: University of Houston


A University of Houston pharmaceutical scientist is developing a new drug which could bring relief to children suffering with Familial Adenomatous Polyposis (FAP), a rare genetic disorder characterized by hundreds – if not thousands – of colorectal polyps. This hereditary cancer predisposition syndrome occurs in 3-per-100,000 live births and, if left untreated, causes colorectal cancer in patients nearly 100 percent of the time. Prior medication for the disease failed because it increased the risk of heart attacks and death.

“If successful, this drug will likely become the first drug for treating children with FAP and will also be useful for colon cancer prevention in other high-risk populations,” said Ming Hu, professor of pharmaceutics, who is using a $200,000 grant from the Cancer Prevention Research Institute of Texas (CPRIT) for a pilot study of the new drug’s effectiveness. Hu’s research team includes Greg Cuny, UH associate professor of medicinal chemistry, and Jason Eriksen, UH associate professor of pharmacology.

Children with FAP have to undergo routine colonoscopy and surgery (removal of polyps and intestinal segments) until the whole colon is eventually removed via colectomy. “The quality of life for children with FAP remains very poor,” said Hu.

Untreated, the disease causes growth of an out-of-control number of polyps that will progress to malignancy. For those who are undiagnosed by age 20, Ming says their life will probably end by 35, because the polyps will become numerous and malignant, leading to severe hemorrhage and deadly metastatic cancer.

To make matters worse, the Food and Drug Administration, which earlier approved the cyclo-oxygenase-2 (COX-2) inhibitor celecoxib to treat FAP, had the FAP indication withdrawn because of the drug’s sometimes fatal toxicity to the heart. Scientists attribute the drug’s toxicity to the fact that it spreads throughout the body, rather than targeting only the affected organs.

COX-2 inhibitors are a type of nonsteroidal anti-inflammatory drugs, many of which have the same non-targeted organ toxicities. To call attention to these severe side effects, the FDA has ordered a “black box” warning be printed on the drug’s package to mark this life-threatening risk. As a result, children with FAP are left with no drugs for treatment.

Hu and his team took this opportunity to develop a more effective treatment through a locally bioavailable COX-2 inhibitor, meaning one that will remain inside the gut area. The new drug is designed to cycle through the colon without escaping to the circulatory system and reaching non-targeted organs. The drug inhibits the production of the molecule called PGE2, which magnifies pain and promotes tumor growth in the colon.

Hu says the drug will also be effective for preventing recurrence after the polyps are removed, which could lead to fewer incidents of colon cancer in high-risk populations.

“Nobody has designed a drug like this, which recycles and limits exposure to the target organ,” said Hu. He has filed a patent on this approach to designing drugs. “If this drug could help save patients and improve their quality of life, it would be a dream come true.”

###

Media Contact
Laurie Fickman
[email protected]
713-743-8454

Original Source

http://www.uh.edu/news-events/stories/2018/november-2018/112018-ming-hu-colon-cancer.php

Tags: BiochemistrycancerInternal MedicineMedicine/HealthPharmaceutical ChemistryPharmaceutical SciencePharmaceutical Sciences
Share25Tweet16Share4ShareSendShare
  • IMAGE

    A new synthesis method for three-dimensional nanocarbons

    64 shares
    Share 26 Tweet 16
  • Within just a few months a deadly epidemic killed all the black sea urchins in the Gulf of Eilat – a great threat to the coral reef in Eilat

    68 shares
    Share 27 Tweet 17
  • How eating natto might help to distress

    64 shares
    Share 26 Tweet 16
  • GPS tracking reveals how a female baboon stopped using urban space after giving birth

    64 shares
    Share 26 Tweet 16
  • Promising building blocks for photonic quantum simulators

    64 shares
    Share 26 Tweet 16
  • Study highlights long-term benefits of family-based care following institutional care

    65 shares
    Share 26 Tweet 16
ADVERTISEMENT

About us

We bring you the latest science news from best research centers and universities around the world. Check our website.

Latest NEWS

Society for Cardiovascular Angiography and Interventions bestows highest designation ranking to leading interventional cardiologists

SCAI announces new award recognizing the contributions of early career interventional cardiologists

Study finds cardiovascular risk score improves after one year of semaglutide use in patients with overweight and obesity

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 206 other subscribers

© 2023 Scienmag- Science Magazine: Latest Science News.

No Result
View All Result
  • HOME PAGE
  • BIOLOGY
  • CHEMISTRY AND PHYSICS
  • MEDICINE
    • Cancer
    • Infectious Emerging Diseases
  • SPACE
  • TECHNOLOGY
  • CONTACT US

© 2023 Scienmag- Science Magazine: Latest Science News.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In